AbbVie Inc. Long Term Debt (Total)

Long Term Debt (Total) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.

Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending September 29, 2019 was $33.1 Billion (a 4.77% increase compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) decreased by -5.36%
  • Annual Long Term Debt (Total) for 2018 was $35 Billion (a 13.08% increase from previous year)
  • Annual Long Term Debt (Total) for 2017 was $31 Billion (a -15.06% decrease from previous year)
  • Annual Long Term Debt (Total) for 2016 was $36.4 Billion (a 24.62% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of AbbVie Inc.

Most recent Long Term Debt (Total)of ABBV including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of AbbVie Inc.

AbbVie Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $33,126.0 $31,619.0 $35,066.0
2018 $35,002.0 $36,487.0 $30,579.0 $30,906.0 $35,002.0
2017 $30,953.0 $33,974.0 $33,817.0 $36,526.0 $30,953.0
2016 $36,440.0 $37,284.0 $37,328.0 $29,490.0 $36,440.0
2015 $29,240.0 $31,359.0 $27,116.0 $10,683.0 $29,240.0
2014 $10,538.0 $14,469.0 $14,470.0 $14,386.0 $10,538.0
2013 $14,292.0 $14,375.0 $14,326.0 $14,601.0 $14,292.0
2012 $14,630.0 $14,630.0
2011 $32.0 $32.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.